[Brokerage Focus] Bocom Intl Cuts cspc pharma (01093) Target Price by 7.9% Indicating significant potential of innovative pipeline BD but high uncertainty in short-term performance.

Jinwu Financial News | bocom intl issued a research report stating that cspc pharma (01093) experienced declines in revenue and net income of 17.8% and 50.4% respectively in Q3 2024, with multiple business sectors under significant pressure. Management expects the company to launch six new products between the end of 2024 and 2025, driving a return to positive growth in operating income outside of BD in 2025, while research and development expenses are anticipated to record double-digit growth as the innovation pipeline accelerates. The bank indicated that BD is about to enter a harvest period: ADC, siRNA, mRNA vaccine platforms are continuously producing new molecules, and key varieties like EGFR-ADC are moving forward.

Golden Guard Financial News20:17 ET

On November 18, cspc pharma repurchased 5.73 million shares at a cost of 29.527 million Hong Kong dollars.

CSPC Pharma (01093.HK) announced on November 18 that it will spend 29.527 million Hong Kong dollars to repurchase 5.73 million shares on November 18, 2024, at a repurchase price of 5.1-5.2 Hong Kong dollars per share.

Gelonghui FinanceNov 18 04:40 ET

CSPC Pharmaceutical Group Limited Just Missed EPS By 38%: Here's What Analysts Think Will Happen Next

Simply Wall StNov 18 02:18 ET

Nomura Adjusts CSPC Pharmaceutical Group's Price Target to HK$7.02 From HK$8.46, Keeps at Buy

MT NewswiresNov 18 02:14 ET · Ratings

[Brokerage Focus] Nomura lowers cspc pharma (01093) target price by 17% due to its poor pharmaceutical sales performance in the third quarter.

Jingwu Financial News | Nomura's research reports indicate that cspc pharma (01093) is expected to have poor pharmaceutical sales performance in the third quarter of 2024, which will drag down the gross margin. The third quarter revenue is 6.4 billion yuan (same below), a year-on-year decrease of 17.8%, lower than Nomura and market expectations. Among them, finished pharmaceutical sales decreased by 20% year-on-year to 5.1 billion yuan; due to weak market demand, the active pharmaceutical ingredient sales decreased by 3.8% year-on-year to 0.871 billion yuan, and functional foods and other sales decreased by 13.7% year-on-year to 0.41 billion yuan. Due to the weak performance in pharmaceutical sales, the gross margin for the third quarter of 2024 narrowed by 3.7 percentage points to 67.6%.

Jingwu Financial NewsNov 18 00:24 ET

CSPC Pharmaceutical's Nine-Month Profit Declines 16%

MT NewswiresNov 15 02:54 ET